The Experts below are selected from a list of 168 Experts worldwide ranked by ideXlab platform
Raymon Vijzelaar - One of the best experts on this subject based on the ideXlab platform.
-
Deletions within COL11A1in Type 2 stickler Syndrome detected by multiplex ligation-dependent probe amplification (MLPA)
BMC Medical Genetics, 2013Co-Authors: Raymon Vijzelaar, Sarah Waller, Abdellatif Errami, Alan Donaldson, Teresa Lourenco, Marcia Rodrigues, Vivienne Mcconnell, Gregory Fincham, Martin Snead, Allan RichardsAbstract:Background COL11A1 is a large complex gene around 250 kb in length and consisting of 68 exons. Pathogenic mutations in the gene can result in Stickler Syndrome, Marshall Syndrome or Fibrochondrogenesis. Many of the mutations resulting in either Stickler or Marshall Syndrome alter splice sites and result in exon skipping, which because of the exon structure of collagen genes usually leaves the message in-frame. The mutant protein then exerts a dominant negative effect as it co-assembles with other collagen gene products. To date only one large deletion of 40 kb in the COL11A1 , which was detected by RT-PCR, has been characterized. However, commonly used screening protocols, utilizing genomic amplification and exon sequencing, are unlikely to detect such large deletions. Consequently the frequency of this type of mutation is unknown. Case presentations We have used Multiplex Ligation-Dependent Probe Amplification (MLPA) in conjunction with exon amplification and sequencing, to analyze patients with clinical features of Stickler Syndrome, and have detected six novel deletions that were not found by exon sequencing alone. Conclusion Exon deletions appear to represent a significant proportion of type 2 Stickler Syndrome. This observation was previously unknown and so diagnostic screening of COL11A1 should include assays capable of detecting both large and small deletions, in addition to exon sequencing.
-
Deletions within COL11A1 in Type 2 stickler Syndrome detected by multiplex ligation-dependent probe amplification (MLPA)
BMC medical genetics, 2013Co-Authors: Raymon Vijzelaar, Sarah Waller, Abdellatif Errami, Alan Donaldson, Teresa Lourenco, Marcia Rodrigues, Vivienne Mcconnell, Gregory S. Fincham, Martin P. Snead, Allan J. RichardsAbstract:COL11A1 is a large complex gene around 250 kb in length and consisting of 68 exons. Pathogenic mutations in the gene can result in Stickler Syndrome, Marshall Syndrome or Fibrochondrogenesis. Many of the mutations resulting in either Stickler or Marshall Syndrome alter splice sites and result in exon skipping, which because of the exon structure of collagen genes usually leaves the message in-frame. The mutant protein then exerts a dominant negative effect as it co-assembles with other collagen gene products. To date only one large deletion of 40 kb in the COL11A1, which was detected by RT-PCR, has been characterized. However, commonly used screening protocols, utilizing genomic amplification and exon sequencing, are unlikely to detect such large deletions. Consequently the frequency of this type of mutation is unknown. We have used Multiplex Ligation-Dependent Probe Amplification (MLPA) in conjunction with exon amplification and sequencing, to analyze patients with clinical features of Stickler Syndrome, and have detected six novel deletions that were not found by exon sequencing alone. Exon deletions appear to represent a significant proportion of type 2 Stickler Syndrome. This observation was previously unknown and so diagnostic screening of COL11A1 should include assays capable of detecting both large and small deletions, in addition to exon sequencing.
Allan Richards - One of the best experts on this subject based on the ideXlab platform.
-
Deletions within COL11A1in Type 2 stickler Syndrome detected by multiplex ligation-dependent probe amplification (MLPA)
BMC Medical Genetics, 2013Co-Authors: Raymon Vijzelaar, Sarah Waller, Abdellatif Errami, Alan Donaldson, Teresa Lourenco, Marcia Rodrigues, Vivienne Mcconnell, Gregory Fincham, Martin Snead, Allan RichardsAbstract:Background COL11A1 is a large complex gene around 250 kb in length and consisting of 68 exons. Pathogenic mutations in the gene can result in Stickler Syndrome, Marshall Syndrome or Fibrochondrogenesis. Many of the mutations resulting in either Stickler or Marshall Syndrome alter splice sites and result in exon skipping, which because of the exon structure of collagen genes usually leaves the message in-frame. The mutant protein then exerts a dominant negative effect as it co-assembles with other collagen gene products. To date only one large deletion of 40 kb in the COL11A1 , which was detected by RT-PCR, has been characterized. However, commonly used screening protocols, utilizing genomic amplification and exon sequencing, are unlikely to detect such large deletions. Consequently the frequency of this type of mutation is unknown. Case presentations We have used Multiplex Ligation-Dependent Probe Amplification (MLPA) in conjunction with exon amplification and sequencing, to analyze patients with clinical features of Stickler Syndrome, and have detected six novel deletions that were not found by exon sequencing alone. Conclusion Exon deletions appear to represent a significant proportion of type 2 Stickler Syndrome. This observation was previously unknown and so diagnostic screening of COL11A1 should include assays capable of detecting both large and small deletions, in addition to exon sequencing.
Allan J. Richards - One of the best experts on this subject based on the ideXlab platform.
-
Deletions within COL11A1 in Type 2 stickler Syndrome detected by multiplex ligation-dependent probe amplification (MLPA)
BMC medical genetics, 2013Co-Authors: Raymon Vijzelaar, Sarah Waller, Abdellatif Errami, Alan Donaldson, Teresa Lourenco, Marcia Rodrigues, Vivienne Mcconnell, Gregory S. Fincham, Martin P. Snead, Allan J. RichardsAbstract:COL11A1 is a large complex gene around 250 kb in length and consisting of 68 exons. Pathogenic mutations in the gene can result in Stickler Syndrome, Marshall Syndrome or Fibrochondrogenesis. Many of the mutations resulting in either Stickler or Marshall Syndrome alter splice sites and result in exon skipping, which because of the exon structure of collagen genes usually leaves the message in-frame. The mutant protein then exerts a dominant negative effect as it co-assembles with other collagen gene products. To date only one large deletion of 40 kb in the COL11A1, which was detected by RT-PCR, has been characterized. However, commonly used screening protocols, utilizing genomic amplification and exon sequencing, are unlikely to detect such large deletions. Consequently the frequency of this type of mutation is unknown. We have used Multiplex Ligation-Dependent Probe Amplification (MLPA) in conjunction with exon amplification and sequencing, to analyze patients with clinical features of Stickler Syndrome, and have detected six novel deletions that were not found by exon sequencing alone. Exon deletions appear to represent a significant proportion of type 2 Stickler Syndrome. This observation was previously unknown and so diagnostic screening of COL11A1 should include assays capable of detecting both large and small deletions, in addition to exon sequencing.
Vivienne Mcconnell - One of the best experts on this subject based on the ideXlab platform.
-
Deletions within COL11A1in Type 2 stickler Syndrome detected by multiplex ligation-dependent probe amplification (MLPA)
BMC Medical Genetics, 2013Co-Authors: Raymon Vijzelaar, Sarah Waller, Abdellatif Errami, Alan Donaldson, Teresa Lourenco, Marcia Rodrigues, Vivienne Mcconnell, Gregory Fincham, Martin Snead, Allan RichardsAbstract:Background COL11A1 is a large complex gene around 250 kb in length and consisting of 68 exons. Pathogenic mutations in the gene can result in Stickler Syndrome, Marshall Syndrome or Fibrochondrogenesis. Many of the mutations resulting in either Stickler or Marshall Syndrome alter splice sites and result in exon skipping, which because of the exon structure of collagen genes usually leaves the message in-frame. The mutant protein then exerts a dominant negative effect as it co-assembles with other collagen gene products. To date only one large deletion of 40 kb in the COL11A1 , which was detected by RT-PCR, has been characterized. However, commonly used screening protocols, utilizing genomic amplification and exon sequencing, are unlikely to detect such large deletions. Consequently the frequency of this type of mutation is unknown. Case presentations We have used Multiplex Ligation-Dependent Probe Amplification (MLPA) in conjunction with exon amplification and sequencing, to analyze patients with clinical features of Stickler Syndrome, and have detected six novel deletions that were not found by exon sequencing alone. Conclusion Exon deletions appear to represent a significant proportion of type 2 Stickler Syndrome. This observation was previously unknown and so diagnostic screening of COL11A1 should include assays capable of detecting both large and small deletions, in addition to exon sequencing.
-
Deletions within COL11A1 in Type 2 stickler Syndrome detected by multiplex ligation-dependent probe amplification (MLPA)
BMC medical genetics, 2013Co-Authors: Raymon Vijzelaar, Sarah Waller, Abdellatif Errami, Alan Donaldson, Teresa Lourenco, Marcia Rodrigues, Vivienne Mcconnell, Gregory S. Fincham, Martin P. Snead, Allan J. RichardsAbstract:COL11A1 is a large complex gene around 250 kb in length and consisting of 68 exons. Pathogenic mutations in the gene can result in Stickler Syndrome, Marshall Syndrome or Fibrochondrogenesis. Many of the mutations resulting in either Stickler or Marshall Syndrome alter splice sites and result in exon skipping, which because of the exon structure of collagen genes usually leaves the message in-frame. The mutant protein then exerts a dominant negative effect as it co-assembles with other collagen gene products. To date only one large deletion of 40 kb in the COL11A1, which was detected by RT-PCR, has been characterized. However, commonly used screening protocols, utilizing genomic amplification and exon sequencing, are unlikely to detect such large deletions. Consequently the frequency of this type of mutation is unknown. We have used Multiplex Ligation-Dependent Probe Amplification (MLPA) in conjunction with exon amplification and sequencing, to analyze patients with clinical features of Stickler Syndrome, and have detected six novel deletions that were not found by exon sequencing alone. Exon deletions appear to represent a significant proportion of type 2 Stickler Syndrome. This observation was previously unknown and so diagnostic screening of COL11A1 should include assays capable of detecting both large and small deletions, in addition to exon sequencing.
Marcia Rodrigues - One of the best experts on this subject based on the ideXlab platform.
-
Deletions within COL11A1in Type 2 stickler Syndrome detected by multiplex ligation-dependent probe amplification (MLPA)
BMC Medical Genetics, 2013Co-Authors: Raymon Vijzelaar, Sarah Waller, Abdellatif Errami, Alan Donaldson, Teresa Lourenco, Marcia Rodrigues, Vivienne Mcconnell, Gregory Fincham, Martin Snead, Allan RichardsAbstract:Background COL11A1 is a large complex gene around 250 kb in length and consisting of 68 exons. Pathogenic mutations in the gene can result in Stickler Syndrome, Marshall Syndrome or Fibrochondrogenesis. Many of the mutations resulting in either Stickler or Marshall Syndrome alter splice sites and result in exon skipping, which because of the exon structure of collagen genes usually leaves the message in-frame. The mutant protein then exerts a dominant negative effect as it co-assembles with other collagen gene products. To date only one large deletion of 40 kb in the COL11A1 , which was detected by RT-PCR, has been characterized. However, commonly used screening protocols, utilizing genomic amplification and exon sequencing, are unlikely to detect such large deletions. Consequently the frequency of this type of mutation is unknown. Case presentations We have used Multiplex Ligation-Dependent Probe Amplification (MLPA) in conjunction with exon amplification and sequencing, to analyze patients with clinical features of Stickler Syndrome, and have detected six novel deletions that were not found by exon sequencing alone. Conclusion Exon deletions appear to represent a significant proportion of type 2 Stickler Syndrome. This observation was previously unknown and so diagnostic screening of COL11A1 should include assays capable of detecting both large and small deletions, in addition to exon sequencing.
-
Deletions within COL11A1 in Type 2 stickler Syndrome detected by multiplex ligation-dependent probe amplification (MLPA)
BMC medical genetics, 2013Co-Authors: Raymon Vijzelaar, Sarah Waller, Abdellatif Errami, Alan Donaldson, Teresa Lourenco, Marcia Rodrigues, Vivienne Mcconnell, Gregory S. Fincham, Martin P. Snead, Allan J. RichardsAbstract:COL11A1 is a large complex gene around 250 kb in length and consisting of 68 exons. Pathogenic mutations in the gene can result in Stickler Syndrome, Marshall Syndrome or Fibrochondrogenesis. Many of the mutations resulting in either Stickler or Marshall Syndrome alter splice sites and result in exon skipping, which because of the exon structure of collagen genes usually leaves the message in-frame. The mutant protein then exerts a dominant negative effect as it co-assembles with other collagen gene products. To date only one large deletion of 40 kb in the COL11A1, which was detected by RT-PCR, has been characterized. However, commonly used screening protocols, utilizing genomic amplification and exon sequencing, are unlikely to detect such large deletions. Consequently the frequency of this type of mutation is unknown. We have used Multiplex Ligation-Dependent Probe Amplification (MLPA) in conjunction with exon amplification and sequencing, to analyze patients with clinical features of Stickler Syndrome, and have detected six novel deletions that were not found by exon sequencing alone. Exon deletions appear to represent a significant proportion of type 2 Stickler Syndrome. This observation was previously unknown and so diagnostic screening of COL11A1 should include assays capable of detecting both large and small deletions, in addition to exon sequencing.